Additional file 6: Figure S6. of Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

Full imaging of Superhance blood flow and GFP from HCT116-GFP mice. Representative image using superhance 680 probe in HCT116 xenograft bearing athymic nude mice after 4 weeks. ONC201: 50 mg/kg every week. Regorafenib: 5 mg/kg daily. Bevacizumab: 5 mg/kg every other week. N=5. (PPTX 469 kb)